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doi:10.1016/j.ejvs.2010.07.029Abstract Introduction: The aim of this study was to establish if an elevated triglyceride to
high-density lipoprotein (HDL) ratio (THR) is not only a risk factor for cardiovascular and overall
morbidity as the updated evidence shows, but could also be employed as a significant predictor
for surgical adverse outcomes and hence be a valid tool for risk stratification of candidates
undergoing abdominal aortic surgery.
Methods: This is a single-centre retrospective analysis of 2224 patients who underwent open
abdominal aortic surgery between January 1996 and 2009. This cohort was divided into quar-
tiles of THR. A list of covariates has been entered with THR into a multiple logistic model with
forwards stepwise selection. The obtained result is an adjusted model, conceived to establish
the association between THR and perioperative adverse events. Discrimination of the model so
obtained and comparison with vascular-specific risk stratification scoring systems were evalu-
ated using the area under the receiver operating characteristic (AUROC).
Results: THR had the highest predictive value for the outcomes of interest. The adjusted odds
ratios (ORs) per every 0.1 augmentation of THR were 1.41 (1.08e1.88) for cardiac, 1.38 (1.09e
1.84) for respiratory, 1.27 (1.06e1.54) for renal adverse events and 1.02 (0.84e1.23) formortality.
Regardingmortality, either of the scoring systemsVascular Physiological andOperative Severity
Score for the enUmeration of Mortality andmorbidity (POSSUM) and customised probability index
(CPI) and the THR ranked as moderate discriminators, with THR performing the worst (AUROC
0.71) compared with Vascular POSSUM (AUROC 0.76) and CPI (AUROC 0.78). THR performed as
a very strong predictor of morbidity (AUROC 0.86), ranking above Vascular POSSUM (AUROC 0.72).education questions on this paper, please go to www.vasculareducation.com and click on ‘CME’.
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250 I. Gambardella et al.Conclusions: THR is a significant predictor of perioperative morbidity and mortality. THR offers
a broad outlook on the metabolic state of patients undergoing major abdominal aortic surgery
and hence their propensity to adverse events, allowing us to risk-stratify the prognostic outcome
of surgical intervention and possibly intervene preoperatively to optimise results.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The risk stratification of patients undergoing surgery has
been a topic attracting the attention of clinical research
over the past decades: the desire to identify higher risk
subjects, in a population of surgical candidates, has led to
the elaboration of different prognostic models.1e4
In parallel, the study of lipoproteins as risk factors
in cardiovascular disease (CVD) and overall morbidity/
mortality has been ongoing, delivering evidence that one of
the best lipoproteic predictors is the triglyceride to high-
density lipoprotein (HDL) ratio (THR). An elevated THR is an
indicator of altered metabolic state, exposing to higher risk
of cardiovascular and overall morbidity/mortality; its
predictive value is superior to the other lipoproteinsmarkers
and is strongly related to hyperinsulinaemia and the overall
concept of metabolic syndrome (MetS).5e10
The aim of this study was to establish if an elevated THR
is not only a risk factor for cardiovascular and overall
morbidity/mortality as the updated evidence shows, but
could also be employed as a significant predictor for
surgical adverse outcomes and hence a valid tool for risk
stratification of candidates undergoing abdominal aortic
surgery.
Methods
Subjects
All vasculopathic patients under clinical follow-up are
screened for lipid profile; when they undergo surgery, their
intra- and perioperative data are entered in our vascular
database. We have analysed and combined the pre-, intra-
and post-(30 days from discharge) operative data of a pop-
ulation of 2342 patients, who underwent major abdominal
aortic surgery over 13 years (January 1996eJanuary 2009)
at the Royal Victoria Hospital (RVH), Belfast,UK.
While Rubin multiple imputation methods were
employed in handling some missing values, listwise deletion
was used only for data lacking homogeneity (e.g., hetero-
geneity of biochemical methodology from different lab
sites). After deletion as specified earlier, the dropout rate
was 5.1% (119 out of 2342 patients), leading to an actual
reservoir of 2224 analysable individuals. This cohort was
composed of 1245 (56%) cases of aneurysmal aorto-iliac
disease and 978 (44%) cases of steno-occlusive aorto-iliac
disease.
Because we believe aortic clamping has to be a common
denominator for all cases to deal with a homogeneous pop-
ulation, endovascular repairs (endovascular aneurysm repair
(EVAR)) were excluded from the aneurysmal cases and the
surgeries not involving aortic clamping (i.e., extra-anatom-
ical procedures) were excluded from the steno-occlusivecases. Every abdominal aortic case undergoing concomitant
infrainguinal surgery was excluded for homogeneity, as it
might affect the incidence of adverse cardiac events.
Parameters and measurements
Specifications about clinical and biochemical covariates’
parameters include hypertension (systolic 140 mmHg and/
or diastolic 90 mmHg and/or current treatment for hyper-
tension);11,12 diabetes (fasting plasma glucose level
126 mgdl1 or current treatment for type I/II diabetes);13
ischaemic/valvular heart disease (already diagnosed or dia-
gnosed at preoperative investigations according to current
guidelines);14 chronic obstructive pulmonary disease (COPD)
(already diagnosed or diagnosed at preoperative pulmonary
function tests (PFTs) according to current guidelines));15
renal dysfunction (already diagnosed or diagnosed at preop-
erative investigations according to current guidelines);16
lipid indicators (lab methods specified below); cerebrovas-
cular accident (CVA) (diagnosed transient ischaemic attack
(TIA)/stroke);17 and infrainguinal disease (diagnosis of PVD
according to The Inter-Society Consensus for Management of
Peripheral Artery Disease (TASC II)).18
Specifications about the outcomes of interest include
fatal/non-fatal myocardial infarction (MI) (clinical, elec-
trophysiological and biochemical parameters according to
the World Health Organization (WHO) redefined criteria);19
respiratory adverse event (clinical, radiological and
mechanical ventilation parameters);15,20 renal adverse
event and sub-clinical acute renal dysfunction (clinical and
biochemical updated parameters);21,22 and 30 days
mortality. MI rates include the symptomatic events and the
sub-clinical events that were detected as an incidental
finding at the pre-discharging electrocardiograph (ECG)
(triggering further investigations when appropriate).
Specifications about analysis of lipid markers: Ethylene
diamine tetraacetic acid (EDTA) 0.1% reservoirs were used
to collect venous blood that, undergoing centrifugation at
3000 rpm for 30 min at 4 C, generated the plasma; the
levels of triglycerides (TGs), total cholesterol (TC), low-
density lipoprotein (LDL) and HDL cholesterol were ana-
lysed on the derived plasma according to Lipid Research
Clinics methods.23,24
For patients with either type I or II diabetes mellitus,
who were nil by mouth in the perioperative phase, the
glycaemic control aimed to maintain routinely the hae-
matic glucose level between 4 and 6 mmol l1 (70e110
mgdl1) via parenteral administration of insulin.
Statistical analysis
The whole population was distributed according to quar-
tiles of THR (TQ).
Table 1 Demographic, clinical, biochemical and social covariates in the population of candidates for open abdominal aortic
surgery, grouped by THR quartiles.
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in binary multiple logistic regression models, calibrating
them for the other 19 covariates in Table 1: these
demographic, clinical and biochemical covariates were
employed as risk adjustors, to clarify the sole effect of THR
on outcomes. Besides the covariates in Table 1, the ratios
TC/HDL and LDL/HDL were calculated and evaluated in the
model.
The list of candidate independent variables (main and
confounders) was first examined for statistical significance
(categorical variables with chi-squared test and metric
variables with univariate logistic regression) and then
added to the multiple logistic model with forwards stepwise
selection.
Odds ratios (ORs) were calculated for those in the
second, third and fourth quartiles of THR compared with
those in the first.
The obtained result is an adjusted model, conceived
to establish the association amongst THR and perioper-
ative adverse events, apart from (and compared with) the
confounders.
The discrimination of themodels was evaluated using the
area under the receiver operating characteristic (AUROC,
that ranges from 0.5 to 1.0): the ROC curve,25,26 obtained by
plotting the true positive rate (TPR) versus the false positiverate (FPR), discriminates suboptimal models (AUROC close
to 0.5) from optimal ones (AUROC closer to 1.0).
THR was constructed as a continuous variable, with an
ongoing shifted threshold of increments of 0.1: the
threshold values, that maximised the AUROC, were identi-
fied for each adverse event. For these outcomes of interest,
adjusted ORs were calculated either for each 0.1 increment
of THR or for the thresholds of THR that optimise it as
predictor.
The performances of two major models, specifically used
to risk-stratify vascular patients (Vascular Physiological and
Operative Severity Score for the enUmeration of Mortality
and morbidity (POSSUM) and customised probability index
(CPI)), were compared to THR in predicting adverse events:
the discrimination of the models was determined and
compared using the AUROC.
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) was
used for statistical analyses.
Results
Demographic (age and male sex), clinical (hypertension,
body mass index (BMI)), biochemical (hyperlipaemia and
diabetes mellitus), social (smoking and alcohol intake) and
surgical (infrainguinal disease and redo surgery) risk
Table 3 Adjusted ORs and 95% CIs for the outcomes of
interest, showing the additional risk per unit increase in
THR.
Adverse event Adjusted OR 95% CI
Major morbidity
- Cardiac 1.41 1.08e1.88
- Respiratory 1.38 1.09e1.84
- Renal 1.27 1.06e1.54
Mortality 1.02 0.84e1.23
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mic heart disease (IHD), chronic renal failure (CRF) or renal
dysfunction and CVA), generally tend to increase from the
first to the last TQ (Table 1).
The incidence of postoperative major morbidities (as
defined above) and mortality in the population, either as
a whole and grouped for TQs, is shown in Table 2. The
overall 30 days mortality was 0.97%; of the 21 deaths, the
cardiac cause prevailed (13 cases, 57%) over the other
causes (pulmonary5 24%, renal2 9.5% and neurological2
9.5%). Mortality was higher in aneurysmal (1.3%) than in
steno-occlusive disease (aortobifemoral/bisiliac 0.7%;
aorto-monofemoral/monoiliac 0.6%; and ilio-femoral 0.3%).
The combined cardiac, respiratory and renal adverse
events rate was 6.5%; according to the gradient of THR,
the percentage of cardiac, respiratory and renal adverse
events increased across the quartiles (P for trend <0.005).
Pre- and postoperative treatments with anti-thrombotic
agents (antiaggregation/coagulation), lipid-lowering agents
(statins and fibrates) and betablockers were not signifi-
cantly different amongst the TQ groups. Preoperatively,
approximately 82% of patients received a form of anti-
aggregation/coagulation, 67% of patients received beta-
blockers and 42% of patients received statins/fibrates.
Angiotensin-converting enzyme (ACE) inhibitors/sartans
were used more often in the last two quartiles (29.4%
< Q2 > 35.7%, P < 0.05). Postoperatively, approximately
94% of patients received anti-thrombotic agents, 89% of
patients received betablockers and 91% of patients
received statins/fibrates; ACE inhibitors/sartans were used
more often in the last two quartiles (29.2% < Q2 > 40.9%,
P < 0.05).
The forward stepwise regression showed THR to have the
highest predictive value for the outcomes of interest,
scoring the lowest P value amongst the other variables.
Specifically, this applied to notorious risk factors, such as
sole lipid markers and diabetes mellitus status; regardless,
the other lipid ratios TC/HDL and LDL/HDL ranked high as
independent predictors; the P value of THR was signifi-
cantly lower in the model.
For each outcome of interest except mortality, there
was a significant additional risk per decimal unit increase of
THR (Table 3): the adjusted ORs (aORs) per every 0.1
augmentation of THR were 1.02 (0.84e1.23) for mortality;Table 2 Percentages of the outcomes of interest, in the whole1.41 (1.08e1.88) for cardiac, 1.38 (1.09e1.84) for respira-
tory and 1.27 (1.06e1.54) for renal adverse events.
THR thresholds that maximised the AUROC for every
outcome of interest were calculated (Table 4): when THR
reached the value of 3.7, patients had aOR of mortality
2.08-(1.14e3.28) fold higher. Regarding morbidity, the aOR
of having cardiac adverse events was 5.27 (2.07e14.03)
times higher when the THR reached a value of 5.6; the aOR
for respiratory event was 4.39 (1.42e13.40) when THR
reached the threshold of 4.8; the aOR for renal adverse
outcome was 2.21 (1.09e4.52) with a THR threshold of 4.6.
The performances of CPI and Vascular POSSUM scoring
systems and THR, as predictors of mortality and overall
major morbidity (summing cardiac, respiratory and renal
adverse events) in our population, were evaluated using the
AUROC as a measure of discrimination (Table 5). Regarding
mortality, all of the three predictors ranked as moderate
discriminators, with THR performing the worst (AUROC
0.71) compared with Vascular POSSUM (AUROC 0.76) and
CPI (AUROC 0.78). THR performed as a very strong predictor
of morbidity (AUROC 0.86), ranking above Vascular POSSUM
(AUROC 0.72).Discussion
The literature shows THR to be a significant predictor of
developing CVD. In the early part of cardiovascular epide-
miology, the role of major risk factors such as a high LDL
concentration, hypertension, low physical activity and
smoking was established.27,28 These major risk factors tendpopulation and amongst THR quartiles.
Table 4 THR thresholds that maximize the AUROC with
related adjusted ORs, for every outcome of interest.
Adverse event THR
threshold
AUROC Adjusted OR (CI)
Major morbidity
- Cardiac 4.6 0.899 5.27 (2.07e14.03)
- Respiratory 3.7 0.804 4.39 (1.42e13.40)
- Renal 4.8 0.790 2.21 (1.09e4.52)
Mortality 5.6 0.788 2.08 (1.14e3.28)
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clinical risk factors (hypertension and BMI), demographic
risk factors (age and male sex), biochemical risk factors
(hyperlipaemia and diabetes mellitus), pre-existing mor-
bidities (COPD, IHD, CRF or renal dysfunction and CVA/TIA),
social risk factors (smoking and alcohol intake) and surgical
risk factors (infrainguinal disease and redo surgery) gener-
ally tend to concentrate in the last TQs (Table 1). In the
adjusted model, none of them alters the significance of THR
as an independent predictor for adverse events.
In our series, the in-hospital mortality was low (0.97%);
relevantly, an increased gradient of THR through the TQs
was associated with a significant raise of in-hospital
mortality and morbidity (Table 2).
For every unit augmentation in THR (Table 3), there was
an increase of about 40% in odds of either cardiac (aOR
1.41, CI 1.08e1.88) or respiratory (aOR 1.38, CI 1.09e1.84)
adverse events, with an augmentation of almost 30% odds
of renal adverse event (aOR 1.27, CI 1.06e1.54). The
increase in odds of mortality per unit augmentation of THR
was not significant (aOR 1.02, CI 0.84e1.23).
The THR thresholds that separate outcome dichotomies
were established analysing the AUROC (Table 4): when THR
is 3.7 there is a fourfold augmentation in respiratory
events; raising the THR (4.6), there is a fivefold increase
in cardiac adverse events, and a twofold increase in renal
adverse events and mortality when the THR is raised to
4.8 and 5.6, respectively.
There seems to be substantial biological support for our
finding that THR is a significant risk factor for perioperativeTable 5 The performance of Vascular POSSUM, Custom-
ized Probability Index and THR in predicting adverse events
are compared utilizing the AUROC as a measure of
discrimination. Morbidity includes cardiac, respiratory and
renal adverse events.
Predictor AUROC
Mortality
- V. POSSUM 0.76 (0.72e0.80)
- CPI 0.78 (0.74e0.83)
- THR 0.71 (0.66e0.75)
Morbidity
- V. POSSUM 0.72 (0.69e0.77)
- THR 0.86 (0.81e0.89)morbidity: we believe our results should be considered with
special reference to the concept of chronic inflammatory
state, as a consequence of MetS.29e31 MetS, characterised
by a lipid profile with high THR, describes the frequent
aggregation of multiple interrelated abnormalities in
glucose and lipid metabolism, hypercoagulation and hy-
pertension in a chronic inflammation setting.29e31 WHO
classifies a subject as affected by MetS when three out of
the following five parameters reach a certain threshold:
waist circumference (>102 cm in men and >88 cm in
women), TG (150 mgdl1), HDL (<40 mgdl1 in men and
<50 mgdl1 in women), blood pressure (130/>85 mmHg)
and fasting glucose (110 mgdl1).32 As all those parame-
ters aggregate significantly in the last quartiles of THR in
our population (Table 1), we can at least relate our results
to the updated literature on MetS.
The high THR lipid profile is an indicator of LDL particle
size, density, distribution and composition: particularly, it
is characterised by a smaller and denser LDL particle5,33
that is more easily oxidised and thus much more thrombo-
atherogenic.34,35 On the other hand, a high level of LDL is
not associated with MetS per se,36 and when a high LDL
level is present with a low THR, the LDL particle is larger,
more buoyant5,6 and less easily oxidised and thus much less
thrombo-atherogenic.34
An increased THR implies an increased amount of TG-rich
lipoproteins, some of which are very thrombo-athero-
genic.37,38 Apolipoprotein B is found in the TG-rich lipopro-
teins, apolipoprotein AeI in HDL: practically, the ratio apoB/
apoA-I is comparable to THR. In the prospective Apolipo-
protein-related MOrtality RISk (AMORIS) study, where more
than 126,000 patients above 40 years of age have been
investigated, the apoB/apoA-I ratio has been proven to be
superior to any of the cholesterol ratiose TC/HDL-C, LDL-C/
HDL-C and non-HDL-C/HDL-C e in predicting the risk of
coronary disease. Moreover, any lipids, lipoproteins or
cholesterol ratios were examined to find out whether they
add significant predictive information beyond that provided
by the apoB/apoA-I ratio. After a mean follow-up of 98
months, 1183 men and 560 women had died from an MI and
their results showed high apoB levels and the apoB/apoA-I
ratio was strongly related to increased coronary risk, while
high apoA-I was inversely related to risk. The apoB/apoA-I
ratio was superior to any of the cholesterol ratios in pre-
dicting risk. This advantagewasmost pronounced in subjects
with LDL-C levels <3.6 mmol l1. The addition of lipids,
lipoproteins or any cholesterol ratio to apoB/apoA-I in risk
models did not further improve the strong predictive value of
apoB/apoA-I.39
A cross-sectional analyses in two community-based
studies (the Penn Diabetes Heart Study PDHS, involving 611
typeII diabetic subjects; the Study of Inherited Risk of
Coronary Atherosclerosis SIRCA that enrolled 803 non-dia-
betic subjects), investigated the supposed superiority of
apoB over LDL in predicting coronary artery calcification
(CAC). In combined analysis of diabetic and non-diabetic
subjects, apoB provided value in predicting CAC scores
beyond LDL-C, total cholesterol, total cholesterol/HDL-C
and marginally beyond non-HDL-C. Plasma apoB, but not
LDL-C, levels were associated with CAC scores in type II
diabetic patients; this demonstrates that apoB levels are
particularly useful in assessing atherosclerotic burden and
254 I. Gambardella et al.cardiovascular risk in type II diabetes.40,41 Indeed, re-
garding the relationship with diabetes, THR is linked to
either hyperinsulinaemia or hyperglycaemia, well-known
risk factors for CVD.7,8
In the West of Scotland Coronary Prevention Study,42
middle-aged men with isolated hypercholesterolaemia
had a 5-year risk of IHD of only 5.3%, whereas middle-aged
men with evidence of MEtS had a 5-year event rate of
14.1%.
An increased THR has been shown to be a powerful
independent predictor not only of cardiac events, but of
all-cause mortality as well. In 544 women without prior MI
or coronary revascularisation, referred for clinically indi-
cated coronary angiography and enrolled in the Women’s
Ischemia Syndrome Evaluation (WISE)study, THR was
a strong independent predictor of mortality in models
adjusted for age, race, smoking, hypertension, diabetes
and angiographic coronary disease severity. For cardiovas-
cular events, the multivariate hazard ratio was 1.54 (95% CI
1.05e2.22, P Z 0.03) when adjusted for demographic and
clinical variables.10
THR with a high value is associated with a hypercoagu-
lable state because of deficient fibrinolysis through higher
levels of plasminogen activator inhibitor-1.46 Both hyper-
coagulable and an enhanced inflammatory state play an
important role in promoting acute cardiovascular events: in
the updated literature, the cardiac event is conceived as
a result of acute dynamic plaque instability, triggered by an
enhanced inflammatory and hypercoagulation state.43e46
In our series, either Vascular POSSUM or CPI scoring
systems or THR have performed as moderate predictors for
mortality, with THR ranking the lowest (Table 5). Vice versa,
THR was a strong predictor of overall major morbidity,
ranking above Vascular POSSUM (CPI is not conceived to
predict morbidity).
The variables contributing to morbidity and resources
use are different from those aggregating in the risk of
mortality. Generalising, the risk factors contributing to in-
hospital and 30-days mortality tend to reflect condition-
specific variables, whereas the factors linked to an increase
in resource use reflect concomitant co-morbidities.3,47,48
Most of the risk stratification models have focussed on
mortality as the main outcome to define effective care.
While mortality is undeniably a fundamental index of
patients’ care, the length and overall costs of hospital-
isation are mostly affected by the morbidity rate.49,50
Conclusions
THR is a significant predictor of perioperative morbidity and
mortality. Regardless of the simplicity of being derived
from routine biochemistry investigations, THR offers
a broad outlook on the metabolic state of patients under-
going abdominal aortic surgery and hence their propensity
to adverse events, allowing us to risk-stratify the prognostic
outcome of surgical intervention and possibly intervene
preoperatively to optimise results.
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